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Management of Late CML RelapseTen years ago, at age 30, a woman underwent bonemarrow transplantation from herHLA-identical brother for
chronic phase CML using busulfan and cyclosphosphamide. Except for grade II acute GVHD, she had an un-
eventful post-transplant course. Yearly testing showed absence of bcr/abl. Now, at age 40, peripheral blood
PCR is positive for bcr/abl and her bone marrow shows 4/20 metaphases with the Ph1 chromosome. Her
CBC is normal, peripheral blood chimerism studies show 96% donor in the granulocyte compartment and
100% donor in the lymphocyte compartment. She has no chronic GVHD, is working full time, and her Karnof-
sky performance status is 100%.
What would you recommend now?
 Treatment with interferon-a
 Donor lymphocyte infusion
 A tyrosine kinase inhibitor
 Second transplantation from the other sibling using a reduced intensity conditioning regimeREADER RESPONSES
In a recent issue of the ASBMT eNEWS, readers
were presented with the above Clinical Challenge
and invited to use an online poll to recommend a course
of treatment. The reader recommendations for ther-
apy were:
51% A tyrosine kinase inhibitor
44% Donor lymphocyte infusion
3% Second transplantation from the other
sibling using a reduced intensity condi-
tioning regime
2% Treatment with interferon-a
COMMENTARY
Approximately half of respondents would treat this
patient with a tyrosine kinase inhibitor. Treatment
with imatinib mesylate has been associated with 62%
complete molecular response in patients treated for
molecular or cytogenetic relapse of CML after trans-
plant[1] with lower rates for patients with hematolog-
ical relapse [2]. Treatment with alpha interferon has
been reported to result in 65% complete cytogenetic
response (CCR) with complete molecular remission
also achieved in some patients [3,4]. However, both in-
terferon and imatinib responses are usually dependent
on continued drug administration. Only 10-25% of
patients attaining molecular remissions with imatinib
are able to discontinue therapy after 6-24 months
and retain their molecular remissions [1]. Thus, theseapproaches do not augment immunologic control of
CML and true disease eradication is unlikely.
While second transplantation from the other
HLA-matched sibling could be considered, the patient
has full donor chimerism, did experience acute
GVHD, and had disease control for 10 years. I would
defer serious consideration of transplantation from
a second donor until it was clear there was no immuno-
logic benefit to using the first donor.
Forty-four percent of respondents would treat this
patient with donor lymphocyte infusion (DLI). DLI
represents an effective approach for management of
recurrent CML after HCT with the highest durable
responses reported in this setting. An 85% molecular
response rate is seen in patients treated for cytogenetic
or molecular relapses alone. However, DLI is
associated with several serious risks, including graft-
versus-host disease (6% - 33%), myelosuppression
(6% - 33%), and treatment-related mortality (4% -
20%). Low dose DLI minimizes some of these risks.
I would recommend treating this patient with low
dose of DLI at 1 x 106 CD3/kg because of the high du-
rable responses and low toxicity reported with this ap-
proach [5-7]. I would monitor her blood for bcr/abl by
PCR and FISH at monthly intervals, repeating a bone
marrow at three month intervals for 6-12 months and
monitoring her CBC at weekly intervals. I would also
monitor her closely for any evidence of GVHD includ-
ing liver function tests and physical examinations at
2-4 week intervals. If no response is observed after847
848 T. M. Wildes6 months following DLI, a 4-8 week course of inter-
feron (1 x 106 units daily) is reasonable to try to opti-
mize the graft-versus-leukemia effect of DLI. If there
is still no response, a second dose of DLI (1 x 107
CD3/kg) could be considered if there are no contrain-
dications such as active GVHD.Concurrent treatment
with interferon-a or tyrosine kinase inhibitors plus
DLI is an option and, if initiated, I would recommend
indefinite administration, although this may not be
necessary in the context of DLI.
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